CN1422641A - Medicine for treating cancerous thoracoascites and preparation method - Google Patents
Medicine for treating cancerous thoracoascites and preparation method Download PDFInfo
- Publication number
- CN1422641A CN1422641A CN 01139793 CN01139793A CN1422641A CN 1422641 A CN1422641 A CN 1422641A CN 01139793 CN01139793 CN 01139793 CN 01139793 A CN01139793 A CN 01139793A CN 1422641 A CN1422641 A CN 1422641A
- Authority
- CN
- China
- Prior art keywords
- semen
- medicine
- pleural fluid
- ascites pleural
- cancerous ascites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The Chinese medicine for curing ascites carcinoma with unique formula preparation method and obvious therapeutic effect is made from 12 Chinese medicinal materials of fresh astragalus root, coix seed, mouning glory seed, zedoary, peach kernel, carthamus flower and others through the processes of grinding and water extraction, etc. and can be made into the conventional dosage forms.
Description
The present invention relates to a kind of medicine for the treatment of cancerous ascites pleural fluid.Be the Chinese patent medicine of feedstock production specifically, the invention still further relates to the preparation method of this medicine with the Chinese herbal medicine.
Cancerous ascites pleural fluid is the late malignant tumour common complication, has stubbornness, big, the recurrent characteristics of amount.The appearance of pernicious ascites pleural fluid is the further virulent performance of disease, and the prompting tumor shifts, and disease has developed into quite serious degree.The appearance of a large amount of ascites pleural fluid has a strong impact on the breathing digestive function, as can not get treating timely and effectively, and the state of an illness is everlasting and is worsened in a short time, dyscrasia occurs, whole body depletion, and prognosis is very poor.
Both at home and abroad to the primary disease Drug therapy, run into following thorny problem at present
1. to give the chemotherapeutics side effect big for whole body and abdominal cavity, and patient is difficult to accept;
2. diuresis Supporting Therapy, lumbar injection biological response modifier effective percentage are low;
3. peritoneovenous shunt is difficult to promote, and many contraindications are arranged.
Late tumor patient appetite is poor, takes difficulty, and external used medicine is not only used convenient but also absorbed soon the curative effect height.The present domestic treatment cancerous ascites pleural fluid Chinese patent medicine that still do not have.
Purpose of the present invention provides a kind of have anticancer, diuresis, raise immunity, the quality of making the life better treatment cancerous ascites pleural fluid medicine.
Another object of the present invention provides the preparation method of this cancerous ascites pleural fluid therapeutic agent.
Solution of the present invention is based on motherland's medical science to pathogenetic understanding of cancerous ascites pleural fluid and Therapeutic Principle, achieve with reference to modern pharmacological research, from motherland's medicine treasure-house, filter out invigorating the spleen and benefiting QI, warming YANG to promote diuresis, the anticancer Chinese crude drug of invigorating blood circulation, by the theory of Chinese medical science prescription, fry in shallow oil its elite, make that its performance is anticancer, diuresis, raise immunity, the mass action of making the life better.
Medicine of the present invention is made by following component: (consumption is a weight portion)
Radix Astragali 30-50 gives birth to each 20-30 Rhizoma Curcumae 30-50 of Semen Coicis 20-40 black and white Semen Pharbitidis
Semen Persicae 15-30 Flos Carthami 15-30 Semen Plantaginis 40-60 Ramulus Cinnamomi 15-30
Polyporus 30-50 Fructus Akebiae 20-40 Pericarpium Arecae 20-40 Borneolum Syntheticum 8-12
Formula optimization weight (part) ratio range of preparation invention medicine is:
Radix Astragali 35-45 gives birth to each 15-30 Rhizoma Curcumae 35-45 of Semen Coicis 25-35 black and white Semen Pharbitidis
Semen Persicae 15-25 Flos Carthami 15-25 Semen Plantaginis 45-55 Ramulus Cinnamomi 15-25
Polyporus 35-45 Fructus Akebiae 25-35 Pericarpium Arecae 25-35 Borneolum Syntheticum 8-10
The optimum weight of medicine of the present invention (part) proportioning is:
Radix Astragali 40 is given birth to each 25 Rhizoma Curcumae 40 of Semen Coicis 30 black and white Semen Pharbitidiss
Semen Persicae 20 Flos Carthamis 20 Semen Plantaginiss 50 Ramulus Cinnamomi 20
Polyporus 40 Fructus Akebiaes 30 Pericarpium Arecae 30 Borneolum Syntheticums 10
Make various dosage forms.
Embodiment:
Radix Astragali 40g gives birth to each 25g Rhizoma Curcumae 40g of Semen Coicis 30g black and white Semen Pharbitidis
Semen Persicae 20g Flos Carthami 20g Semen Plantaginis 50g Ramulus Cinnamomi 20g
Polyporus 40g Fructus Akebiae 30g Pericarpium Arecae 30g Borneolum Syntheticum 10g.
Preparation method:
(1) get Semen Coicis, drying and crushing is to 120 order fine powders;
(2) get Borneolum Syntheticum, converting of ethanol.
(3) the other medicines decocting in water is 2-3 time, and each 1～1.5 hour, removing slag was concentrated into thick paste.
(4) (1), (2), (3) medicine are mixed, add sodium carboxymethyl cellulose, the mixing batter bottling is for disappearing water II number.
This medical instrument of important feature of the present invention has slow release, long lasting characteristics, can not only be distributed to whole body by blood circulation behind the transdermal, and dense poly-onset in target site-ascites.After offseting the drug of topical application of water II abdominal part with gas chromatography, the quantitative Transdermal absorption of Borneolum Syntheticum detects, promptly in seroperitoneum, measured Borneolum Syntheticum in 2 hours, concentration has only 0.236ug/ml, subsequent concn slowly rises, and reaches peak value between 24 hours～36 hours, average out to 2.303ug/ml, slowly descend then, to 84 hours about 0.319mg/ml.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1. to select for use medicine to be pharmacopeia contained in the present invention, and each component meets the pharmaceutical control law regulation.
2. medicine external, easy to use, drug absorption is good, the curative effect height, toxic and side effects is few.
For showing the therapeutic effect of medicine of the present invention to cancerous ascites pleural fluid, the present invention is through the clinical observation of 60 routine cancer ascites patient systems, be divided into external application of Chinese medicine group (31 example), cisplatin matched group (29 example), two groups of patient's age, sex, sick kind and clinical stagess, quality of life scoring, the course of disease be no significant difference all.
The cisplatin matched group: after emitting a certain amount of ascites behind the abdominal paracentesis, add dexamethasone 5mg lumbar injection with cisplatin 60mg, 1 time weekly, totally 4 times; External application of Chinese medicine group: abdomen is worn art and is emitted a certain amount of ascites, presses the 2ml/kg administration, and area is big as far as possible, and medicine was kept on stomach wall 24～36 hours, one applies every other day, counts 30 days.
Clinical test results such as following table:
As can be seen from Table 1, the ascites effective percentage external application of Chinese medicine group (87.1%) that disappears obviously is better than cisplatin group (58.6%), P＜0.05.
As can be seen from Table 2, B ultrasonic is surveyed the straight footpath of maximum liquid of ascites, and external application of Chinese medicine group is reduced to 3.93cm before treating, and the cisplatin group reduces 2.24cm than before treating.
Table 3, table 4 disappear for clinical symptoms improvement situation after the water II application, and when reducing ascites, most of patients feels that the abdominal distention bearing down alleviates, abdominal muscular relaxation, and aerofluxus and defecation increase, and appetite is improved, and spirit takes a turn for the better; Abdominal circumference obviously reduces after the medication, and external application of Chinese medicine group abdominal circumference dwindles average out to 6.4cm, and the cisplatin group is 4.25cm.
Table 5 prompting patient's carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), ovarian cancer related antigen (CA125) all reduce to some extent, and external application of Chinese medicine group is suitable with the cisplatin group.
As can be seen from Table 6, the observation before and after treatment shows to part patient T cell subsets and NK cytoactive: disappear and come raise immunity by adjusting percentage of lymphocyte and activity water II number.Treatment back cisplatin group CD
3Increase CD
4, CD
8Have no significant change, both ratios reduce before treating; External application of Chinese medicine group CD3 and CD
4Obviously increase CD
8Slightly raise CD
4/ CD
8Ratio obviously raises, and has compared marked difference (P＜0.05) with the cisplatin group.The NK cytoactive is all very low before treatment, and DDP group in treatment back does not have obviously and changes, and the external application group obviously raises, and compares that there were significant differences (P＜0.05) for two groups..
Other no blood toxicity that disappears water II number, and can improve the impaired hepatic and renal function of carcinous patients with ascites in late period in various degree.
The situation that disappears group example number CR PR effective percentage (%) cisplatin group 29 3 14 58.6 Chinese medicines of table 1 cancer ascites are to external application group 31 7 20 87.1
Table 2 B ultrasonic is surveyed the variation group in the straight footpath of the maximum liquid of ascites
The maximum straight footpath of liquid (cm) of ascites
Cisplatin group 8.97 ± 2.41 6.73 ± 3.51 2.24 external application of Chinese medicine groups 9.07 ± 2.16 5.14 ± 3.47 3.93 are reduced in the treatment back before the treatment
Table 3 clinical symptoms is improved situation group abdominal muscular relaxation aerofluxus increase urine number of times stimulating appetite and is improved spiritual improvement cisplatin group 18 (62.1%) 6 (20.7%) 9 (31.0) % 5 (17.2%) 11 (37.9%) external application of Chinese medicine groups 26 (83.9%) 27 (87.1%) 25 (80.6%) 24 (77.4%) 26 (83.9%)
Table 4 abdominal circumference and urine amount change situation group abdominal circumference reduction (cm) twenty-four-hour urine amount recruitment (ml) cisplatin group 4.25 ± 2.24 260.4 ± 167.4 external application of Chinese medicine group 6.40 ± 3.31 562.8 ± 188.7P＜0.01＜0.01
Table 5 tumor markers 54.8 ± 12.3 571.6 ± 498.2 186.9 ± 80.5 external application of Chinese medicine groups after the treatment of variation group CEA (ng/ml) AFP (ng/ml) CA125 (v/ml) the cis-platinum group before and after the treatment front 97.5 ± 88.4 1269.5 ± 1207.4 357.3 ± 348.9 is treated are treated front 105.6 ± 121.4 1064.3 ± 1987.2 298.4 ± 385.2 and are treated rear 63.9 ± 22.5 628.5 ± 416.9 147.5 ± 46.3
Table 6 T cell subsets and NK cytoactive variation group t lymphocyte subset group (%) the NK cell before and after treatment
CD
3CD
4CD
8CD
4/ CD
853.7 ± 14.8 12.6 ± 7.7 45.8 ± 12.7 0.275 4.35 ± 4.06 external application of Chinese medicine groups were treated front 42.9 ± 15.8 16.8 ± 8.0 44.5 ± 13.6 0.378 4.62 ± 4.13 and are treated rear 78.3 ± 16.4 37.9 ± 7.6 26.1 ± 12.8 1.452 after active (%) cis-platinum group treatment front 47.5 ± 16.3 13.9 ± 8.5 43.6 ± 12.0 0.319 4.89 ± 4.21 was treated* △11.85 ± 5.99
* △
Annotate:
*Show with the cisplatin group than P＜0.05; △ shows and treats front and back than P＜0.05.
Claims (6)
1. medicine for the treatment of cancerous ascites pleural fluid is characterized in that it is the medicament of being made by the raw material of following weight parts:
Radix Astragali 30-50 gives birth to each 20-30 Rhizoma Curcumae 30-50 of Semen Coicis 20-40 black and white Semen Pharbitidis
Semen Persicae 15-30 Flos Carthami 15-30 Semen Plantaginis 40-60 Ramulus Cinnamomi 15-30
Polyporus 30-50 Fructus Akebiae 20-40 Pericarpium Arecae 20-40 Borneolum Syntheticum 8-12.
2. the medicine of treatment cancerous ascites pleural fluid according to claim 1, wherein the weight portion of each raw material is:
Radix Astragali 35-45 gives birth to each 15-30 Rhizoma Curcumae 35-45 of Semen Coicis 25-35 black and white Semen Pharbitidis
Semen Persicae 15-25 Flos Carthami 15-25 Semen Plantaginis 45-55 Ramulus Cinnamomi 15-25
Polyporus 35-45 Fructus Akebiae 25-35 Pericarpium Arecae 25-35 Borneolum Syntheticum 8-10.
3. the medicine of treatment cancerous ascites pleural fluid according to claim 1, wherein the weight portion of raw material is:
Radix Astragali 40 is given birth to each 25 Rhizoma Curcumae 40 of Semen Coicis 30 black and white Semen Pharbitidiss
Semen Persicae 20 Flos Carthamis 20 Semen Plantaginiss 50 Ramulus Cinnamomi 20
Polyporus 40 Fructus Akebiaes 30 Pericarpium Arecae 30 Borneolum Syntheticums 10.
4. according to the medicine of claim 1,2 or 3 described treatment cancerous ascites pleural fluid, it is characterized in that said medicament is a said dosage form on any pharmaceutics.
5. the medicine of treatment cancerous ascites pleural fluid according to claim 4 is characterized in that said medicament is an externally used paste.
6. the process for preparing medicine of the described treatment cancerous ascites pleural fluid of claim 5 is characterized in that being concentrated into thick paste in 1-1.5 hour except that giving birth to Semen Coicis, all the medical material decocting in water of Borneolum Syntheticum 2-3 time at every turn; Give birth to Semen Coicis and grind into powder, be ground into 120 order fine powders; Borneolum Syntheticum is with 95% converting of ethanol; Each organizes the medicine mixing, adds sodium carboxymethyl cellulose and applies type, the mixing batter bottling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01139793 CN1422641A (en) | 2001-12-05 | 2001-12-05 | Medicine for treating cancerous thoracoascites and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01139793 CN1422641A (en) | 2001-12-05 | 2001-12-05 | Medicine for treating cancerous thoracoascites and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1422641A true CN1422641A (en) | 2003-06-11 |
Family
ID=4675419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01139793 Pending CN1422641A (en) | 2001-12-05 | 2001-12-05 | Medicine for treating cancerous thoracoascites and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1422641A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055186A (en) * | 2013-01-31 | 2013-04-24 | 邵宏敏 | External traditional Chinese medicine for treating ascites |
| CN103055078A (en) * | 2012-12-26 | 2013-04-24 | 柳州市中医院 | Traditional Chinese medicine for treating ascites hepatoma and preparation method thereof |
| CN101700382B (en) * | 2009-11-12 | 2014-12-10 | 张国营 | Cancer pain elimination pill |
| CN105031532A (en) * | 2015-07-31 | 2015-11-11 | 长兴县中医院 | Traditional Chinese medicine composition for treating seroperitoneum and preparation thereof |
| CN106177811A (en) * | 2016-08-31 | 2016-12-07 | 王清贤 | A kind of external application Chinese medicine treating pernicious ascites pleural fluid and usage thereof |
-
2001
- 2001-12-05 CN CN 01139793 patent/CN1422641A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700382B (en) * | 2009-11-12 | 2014-12-10 | 张国营 | Cancer pain elimination pill |
| CN103055078A (en) * | 2012-12-26 | 2013-04-24 | 柳州市中医院 | Traditional Chinese medicine for treating ascites hepatoma and preparation method thereof |
| CN103055078B (en) * | 2012-12-26 | 2014-09-17 | 柳州市中医院 | Traditional Chinese medicine for treating ascites hepatoma and preparation method thereof |
| CN103055186A (en) * | 2013-01-31 | 2013-04-24 | 邵宏敏 | External traditional Chinese medicine for treating ascites |
| CN103055186B (en) * | 2013-01-31 | 2013-11-27 | 邵宏敏 | External traditional Chinese medicine for treating ascites |
| CN105031532A (en) * | 2015-07-31 | 2015-11-11 | 长兴县中医院 | Traditional Chinese medicine composition for treating seroperitoneum and preparation thereof |
| CN106177811A (en) * | 2016-08-31 | 2016-12-07 | 王清贤 | A kind of external application Chinese medicine treating pernicious ascites pleural fluid and usage thereof |
| CN113413450A (en) * | 2016-08-31 | 2021-09-21 | 王清贤 | Traditional Chinese medicine composition for treating malignant pleural effusion and ascites as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1305513C (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN101062146A (en) | Chinese traditional medicine for treating gastric cancer and bone cancer | |
| CN102688317A (en) | Traditional Chinese medicine for treating liver cancer | |
| CN102626508B (en) | Traditional Chinese medicine composite for curing liver cancer | |
| CN1422641A (en) | Medicine for treating cancerous thoracoascites and preparation method | |
| CN1895337A (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving late tumor patient life quality | |
| CN1686404A (en) | Dangshen astragalus composition for regulating immunity and its preparation method | |
| CN1846773A (en) | Bladder cancer treating Chinese medicine prepn | |
| CN1237985C (en) | Traditional Chinese medicine injection for treating tumor and preparation process thereof | |
| CN1225258C (en) | Chinese medicine compound preparation for curing pancreatic cancer | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN101036723A (en) | Effective Chinese traditional medicine having a function of invigorating kidney and strengthening resistance and solidifying health | |
| CN1836702A (en) | Medicine for treating tumour and its preparing method | |
| CN101675961B (en) | A medicinal preparation for treating breast cancer and preparation method thereof | |
| CN1242790C (en) | Composition for improving life quality of cancer patients | |
| CN1140071A (en) | Anticancer drug and preparing method thereof | |
| CN1742820A (en) | Stomach-power Chinese medicine preparation and preparing method | |
| CN100349585C (en) | Dampness dispersing, cancer resisting medicine, its preparation method and its application in the process for preparing anticancer medicine | |
| CN107362296B (en) | Medicine for treating benign tumor of skin and preparation method thereof | |
| CN1192365A (en) | Traditional Chinese medicine for treating mastosis | |
| CN102824334A (en) | Anti-cancer drug | |
| CN1679908A (en) | Chinese medicine for treating tumor and preparation thereof | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN101596237A (en) | A kind of Chinese medicine preparation for the treatment of chronic myelocytic leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |